Dr Gary Clark is Metrion’s Director of Screening Technologies and has over 25 years of experience in ion channel drug discovery, including more than 20 years in contract research. At Metrion, Gary is responsible for overseeing screening strategy and delivery, with a particular focus on ion channel assay development, automated electrophysiology, and high-throughput screening platforms.

Gary began his career in biotech, where he was closely involved in the early development and adoption of automated patch-clamp technologies. In 2005, he joined BioFocus (now Charles River) as a Team Leader, where he successfully implemented automated electrophysiology capabilities for contract research applications.

During his time at BioFocus and Charles River, Gary led numerous client ion channel programmes across the preclinical pipeline, including assay development, cell line generation, high-throughput screening, and hit-to-lead/lead optimisation. His work has spanned several therapeutic areas, with a particular emphasis on pain and respiratory indications.

Gary holds a BSc (Hons) in Zoology and Physiology from Royal Holloway, University of London, and earned his PhD in cardiac electrophysiology from Coventry University. He is the author of peer-reviewed publications in the field.